Reply to N. Personeni et al

J Clin Oncol. 2017 Jul 1;35(19):2214-2215. doi: 10.1200/JCO.2017.72.9293. Epub 2017 May 4.

Authors

Richard Jackson¹, Efty Psarelli¹, Philip J Johnson¹

Affiliation

¹ Richard Jackson, Efty Psarelli, and Philip J. Johnson, University of Liverpool, Liverpool, United Kingdom.

PMID: 28471710
DOI: 10.1200/JCO.2017.72.9293

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Hepatocellular*
Hepacivirus
Humans
Liver Neoplasms*
Prostatic Neoplasms*
Sorafenib

Substances

Sorafenib